Jeffrey Lancet, MD, currently serves as the Chair and Program Leader for the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, FL.
Dr Lancet received his medical degree from the State University of New York Upstate Medical University in Albany, NY. He then completed a residency in internal medicine and a fellowship in hematology/oncology at the University of Rochester in Rochester, NY, before relocating to the Moffit Cancer Center in 2004.
Speaking on novel therapies for AML
Dr Lancet has a special interest in the design and conduct of early phase clinical trials in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms. Dr Lancet is the principal investigator of many clinical trials investigating the use of novel therapies in AML and MDS.